Market Overview

Jefferies Initiates Kite Pharma At Buy


Analysts at Jefferies initiated coverage on shares of Kite Pharma (NASDAQ: KITE) with a Buy rating.

The target price for Kite Pharma is set to $35.

Kite Pharma's shares gained 1.95% to close at $24.05 yesterday.

Latest Ratings for KITE

Aug 2017UpgradesUnderperformNeutral
Aug 2017DowngradesBuyHold
Aug 2017DowngradesBuyHold

View More Analyst Ratings for KITE
View the Latest Analyst Ratings

Posted-In: JefferiesInitiation Analyst Ratings


Related Articles (KITE)

View Comments and Join the Discussion!

Latest Ratings

WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: JPMorgan Posts Upbeat Q2 Profit, Shares Gain

#PreMarket Primer: Tuesday, July 15: Citigroup Settles Mortgage Probe